BLASUBCUTANEOUSINJECTABLE1 Generic Approved
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TYENNE (tocilizumab-aazg) by Fresenius Kabi is interleukin 6 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYENNE (tocilizumab-aazg) is a monoclonal antibody targeting the interleukin-6 receptor, representing a biosimilar formulation of an established IL-6 antagonist. It is administered subcutaneously and is indicated for inflammatory conditions responsive to IL-6 pathway modulation. This product enters a mature but growing therapeutic category with established clinical benefit and safety profiles.
Growth
Early-stage growth product with moderate competitive intensity (30% pressure) offers opportunity for rapid market share capture and team expansion in commercial and medical affairs roles.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TYENNE offers early-career growth opportunities in a newly approved biosimilar with near-term revenue scaling potential. Roles emphasize payer negotiation, physician education, and supply chain reliability rather than clinical discovery or rare disease expertise.
Brand ManagerMedical Science Liaison
Worked on TYENNE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.